中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.014 seconds)

    2,3,4-Trinor-m-inter-phenylene-prostaglandin derivatives and compositions and method for inhibiting blood platelet aggregation
    2.
    发明授权
    2,3,4-Trinor-m-inter-phenylene-prostaglandin derivatives and compositions and method for inhibiting blood platelet aggregation 失效
    2,3,4-三硝基间亚苯基前列腺素衍生物及其抑制血小板聚集的组合物和方法

    公开(公告)号：US4451483A

    公开(公告)日：1984-05-29

    申请号：US367068

    申请日：1982-04-09

    Applicant: Istvan Szekely ,  Krisztina Kekesi ,  Mariann Lovasz nee Gaspar ,  Sandor Botar ,  Pal Hadhazy ,  Istvan Rakoczi ,  Laszlo Muszbek ,  Judit Skopal ,  Istvan Stadler ,  Karoly Horvath ,  Gabor Kovacs ,  Peter Kormoczy

    Inventor： Istvan Szekely ,  Krisztina Kekesi ,  Mariann Lovasz nee Gaspar ,  Sandor Botar ,  Pal Hadhazy ,  Istvan Rakoczi ,  Laszlo Muszbek ,  Judit Skopal ,  Istvan Stadler ,  Karoly Horvath ,  Gabor Kovacs ,  Peter Kormoczy

    IPC: A61K31/5575 ,  C07C405/00 ,  C07D307/937 ,  A61K31/34 ,  C07D307/935

    CPC classification number: C07D307/937 ,  C07C405/00 ,  C07C405/0041 ,  Y10S514/822

    Abstract: 2,3,4-trinor-1,5-inter-m-phenylene-prostacycline derivatives of the formula (I), ##STR1## wherein R.sup.1 is hydrogen, a C.sub.1-4 alkyl group, an alkali metal cation or a primary, secondary, tertiary or quaternary ammonium cation,R.sup.2 and R.sup.3 each represent hydrogen or a C.sub.1-4 alkanoyl, benzoyl, substituted benzoyl, tetrahydropyranyl, ethoxyethyl or tri-(C.sub.1-4 alkyl)-silyl group,R.sup.4 is hydrogen or a C.sub.1-4 alkyl group, andR.sup.5 is a hexyl, heptyl, phenoxymethyl or m-trifluoromethylphenoxymethyl group, orR.sup.5 represents a group of the general formula ##STR2## and in this latter formula Z is an amino group or an optionally halo-substituted C.sub.1-4 alkanoylamino, benzoylamino or tosylamino group, andR.sup.6 is a C.sub.4-6 alkyl, phenyl or benzyl group,are prepared by reacting a bicyclic lactol of the formula (II), ##STR3## with a reactive phosphorane prepared from a triphenyl-m-carbobenzylphosphonium halide and a strong base, optionally esterifying the resulting prostaglandin derivative and, whenever it contains a free amino group, protecting this amino group by acylation, reacting then the prostaglandin derivative with an electrophilic reagent of the formula E-X, wherein X is halogen atom and E is halogen atom or an acetyl, trifluoroacetyl or N-succinimido group, and subjecting the resulting halogenated PGI.sub.1 derivative to hydrogen halide elimination. The compounds of the formula (I) possess valuable biological effects and can be applied in therapy primarily as blood platelet aggregation inhibiting agents.

    Abstract translation: 式（I）的2,3,4-三硝基-1,5-间 - 间 - 亚苯基 - 前列环素衍生物，其中R 1是氢，C 1-4烷基，碱金属阳离子或 伯，仲，叔或季铵阳离子，R2和R3各自表示氢或C1-4烷酰基，苯甲酰基，取代的苯甲酰基，四氢吡喃基，乙氧基乙基或三（C1-4烷基） - 甲硅烷基，R4是氢或 C 1-4烷基，R 5为己基，庚基，苯氧基甲基或间三氟甲基苯氧基甲基，或R 5表示通式“IMAGE”的基团，在后一式中Z为氨基或任意卤素取代的C1 -4烷酰基氨基，苯甲酰氨基或甲苯磺酰氨基，R6是C4-6烷基，苯基或苄基，是通过使式（II）的双环内酰醇与式（II）的双环内酰醇与由 三苯基-m-苄基苄基卤化鏻和强碱，任选地酯化所得的前列腺素衍生物，并且每当其含有时 游离氨基，通过酰化保护该氨基，然后将前列腺素衍生物与式EX的亲电试剂反应，其中X是卤素原子，E是卤素原子或乙酰基，三氟乙酰基或N-琥珀酰亚胺基，并使 得到的卤化PGI1衍生物消除卤化氢。 式（I）化合物具有有价值的生物学效应，可用作主要作为血小板聚集抑制剂的治疗。

    13-Thia-prostacycline derivatives
    3.
    发明授权
    13-Thia-prostacycline derivatives 失效
    13-前列环素衍生物

    公开(公告)号：US4425358A

    公开(公告)日：1984-01-10

    申请号：US370503

    申请日：1982-04-21

    Applicant: Csaba Szantay ,  Lajos Novak ,  Jozsef Aszodi ,  Vilmos Simonidesz ,  Geza Galambos ,  Gabor Kovacs ,  Sandor Virag ,  Istvan Stadler ,  Peter Kormoczy

    Inventor： Csaba Szantay ,  Lajos Novak ,  Jozsef Aszodi ,  Vilmos Simonidesz ,  Geza Galambos ,  Gabor Kovacs ,  Sandor Virag ,  Istvan Stadler ,  Peter Kormoczy

    IPC: C07D307/935 ,  A61K31/557 ,  A61P7/02 ,  A61P9/12 ,  C07C405/00 ,  C07D307/937 ,  C07D407/12

    CPC classification number: C07D307/937 ,  C07C405/0033 ,  C07D407/12 ,  Y10S514/822

    Abstract: The invention relates to new optically active or racemic 13-thia-prostacycline derivatives of the Formula I ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable cation or a straight or branched chain alkyl group having 1-5 carbon atoms;R.sup.2 is straight or branched chain alkyl having 4-9 carbon atoms or monosubstituted phenoxymethyl;--A--B-- is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH-- of Z-- or E-- configuration or --C.tbd.C--;one of the symbols X and Y is hydrogen, methyl or ethyl and the other is hydroxy, tetrahydropyranyoxy, 1-ethoxy-ethoxy or trialkylsilyloxy; orX and Y together form a --O--CH.sub.2 --CH.sub.2 --O-- group;Z is a sulfur atom or a --SO-- group.The compounds of the Formula I can be prepared by reacting a 13-thia-prostaglandine of the Formula III ##STR2## if desired after oxidation into the corresponding 13-oxide derivative--with a halogenating agent; and treating the 5-halogeno-13-thia-prostacycline of the Formula II ##STR3## thus obtained wherein E is halogen with an organic or inorganic base; and thereafter if desired removing the protecting groups X and/or Y and if desired converting a compound of the Formula I obtained into a salt or setting free the same from a salt. The new compounds of the Formula I possess anti-coagulant and hypotensive properties and can be used in therapy.

    Abstract translation: 本发明涉及式I的新的光学活性或外消旋的13-前列环素衍生物，其中R1是氢，可药用阳离子或具有1-5个碳原子的直链或支链烷基; R2是具有4-9个碳原子的直链或支链烷基或单取代的苯氧基甲基; -A-B-是Z-或E-构型的-CH 2 -CH 2 - ， - CH = CH-或-C 3 D C-; 符号X和Y之一是氢，甲基或乙基，另一个是羟基，四氢吡喃基氧基，1-乙氧基 - 乙氧基或三烷基甲硅烷氧基; 或X和Y一起形成-O-CH 2 -CH 2 -O-基团; Z是硫原子或-SO-基。 式I的化合物可以通过使式III的13-前 - 前列腺素（III）反应来制备。

    Sulfur-containing isoquinoline derivatives in pharmaceutical compositions and methods of use
    4.
    发明授权
    Sulfur-containing isoquinoline derivatives in pharmaceutical compositions and methods of use 失效
    含硫异喹啉衍生物在药物组合物和使用方法中的应用

    公开(公告)号：US4425349A

    公开(公告)日：1984-01-10

    申请号：US381775

    申请日：1982-05-25

    Applicant: Kalman Takacs ,  Maria H. Papp ,  Gabor Kovacs ,  Ilona K. Ajzert ,  Antal Simay ,  Peter Literati Nagy ,  Marian E. Puskas ,  Gyula Sebestyen ,  Istvan Stadler ,  Zoltan Sumeghy

    Inventor： Kalman Takacs ,  Maria H. Papp ,  Gabor Kovacs ,  Ilona K. Ajzert ,  Antal Simay ,  Peter Literati Nagy ,  Marian E. Puskas ,  Gyula Sebestyen ,  Istvan Stadler ,  Zoltan Sumeghy

    IPC: C07D217/14 ,  C07D513/04 ,  A61K31/47

    CPC classification number: C07D513/04 ,  C07D217/14 ,  Y10S514/826 ,  Y10S514/869

    Abstract: The invention concerns new sulfur-containing isoquinoline derivatives. More particularly, the invention relates to isoquinoline derivatives of the general formula (I) ##STR1## wherein R independently represents hydrogen, hydroxyl or alkoxy having 1 to 4 carbon atoms,R.sup.1 is hydrogen, alkyl having 1 to 4 carbon atoms and optionally substituted with phenyl, phenyl optionally substituted with one or more halogen or alkoxy group, cyano or carbamoyl,R.sup.2 is phenyl optionally substituted with one or more halogen, alkoxy or carboxyl, or a group of the general formula A ##STR2## wherein R.sup.3 is hydrogen, a straight or branched chained alkyl having 1 to 4 carbon atoms or phenyl,m and n independently represent 0, 1 or 2, with the proviso that m+n is at least 1,R.sup.4 is hydrogen, phenyl, hydroxyl, acyloxy, carboxyl, alkoxycarbonyl having 1 to 6 carbon atoms, carbamoyl, carbazoyl or dialkylamino containing 1 to 6 carbon atoms in the alkyl moiety, orR.sup.2 is a straight or branched chained alkylene group having 1 to 6 carbon atoms, andthe dotted line stands for a further carbon-carbon bond or hydrogen atoms in the 3- and 4-positions of the ring,and salts and cyclic amides thereof.The new compounds possess valuable pharmaceutical activities, more particularly, are potent diuretic, antiasthmatic, hypotensive and antiinflammatory agents. Thus another aspect of the invention is a pharmaceutical composition which comprises as active ingredient a pharmaceutically effective amount of at least one compound of the general formula (I) with at least one pharmaceutically inert carrier or diluent. The invention also relates to a process for preparing these compounds.

    Abstract translation: 本发明涉及新的含硫异喹啉衍生物。 更具体地说，本发明涉及通式（I）的异喹啉衍生物，其中R独立地表示氢，羟基或具有1至4个碳原子的烷氧基，R 1是氢，具有1至4个碳原子的烷基和 任选地被苯基取代，任选被一个或多个卤素或烷氧基取代的苯基，氰基或氨基甲酰基，R 2是任选被一个或多个卤素，烷氧基或羧基取代的苯基或通式A的基团，其中R 3是 氢，具有1至4个碳原子的直链或支链烷基或苯基，m和n独立地表示0,1或2，条件是m + n至少为1，R4为氢，苯基，羟基，酰氧基， 羧基，具有1至6个碳原子的烷氧基羰基，在烷基部分含有1至6个碳原子的氨基甲酰基，咔唑基或二烷基氨基，或者是具有1至6个碳原子的直链或支链的亚烷基，虚线代表 进一步c 环的3-和4-位的碳 - 碳键或氢原子，及其盐和环状酰胺。 新化合物具有有价值的药物活性，特别是有效的利尿，止喘，降压和抗炎药。 因此，本发明的另一方面是药物组合物，其包含作为活性成分的药学有效量的至少一种通式（I）的化合物与至少一种药学上惰性的载体或稀释剂。 本发明还涉及制备这些化合物的方法。

    Interfuranylene prostacyclins
    5.
    发明授权
    Interfuranylene prostacyclins 失效
    二烯呋喃前列环素

    公开(公告)号：US4740523A

    公开(公告)日：1988-04-26

    申请号：US820434

    申请日：1986-01-17

    Applicant: Geza Galambos ,  Jozsef Ivanics ,  Gyorgy Dorman ,  Karoly Kanay ,  Istvan Tomoskozy ,  Gabor Kovacs ,  Istvan Stadler ,  Peter Kormoczi ,  Pal Hadhazy ,  Sandor Virag ,  Miklos Kiss

    Inventor： Geza Galambos ,  Jozsef Ivanics ,  Gyorgy Dorman ,  Karoly Kanay ,  Istvan Tomoskozy ,  Gabor Kovacs ,  Istvan Stadler ,  Peter Kormoczi ,  Pal Hadhazy ,  Sandor Virag ,  Miklos Kiss

    IPC: C07C405/00 ,  A61K31/35 ,  A61K31/557 ,  A61K31/5585 ,  A61P7/02 ,  A61P9/12 ,  A61P9/14 ,  A61P11/08 ,  A61P35/00 ,  C07D307/935 ,  C07D311/02 ,  C07D407/04 ,  C07D407/14 ,  C07D311/00

    CPC classification number: C07D407/04

    Abstract: The invention relates to novel interfuranylene-prostacyclin derivatives of the general formula (I) ##STR1## wherein R.sup.1 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group, an inorganic cation or for the protonated form of a base containing an amino group;R.sup.2 stands for hydrogen, a C.sub.1-4 alkanoyl or benzoyl group, a monosubstituted benzoyl, trialkylsilyl or an alkoxyalkyl group;R.sup.3 stands for a straight or branched chain C.sub.1-6 alkyl group, a phenyl group optionally substituted by halogen or by a C.sub.1-4 alkyl group, a heteroaryl group optionally substituted by halogen or by a C.sub.1-4 alkyl group or a cycloalkyl group;A stands for an ethylene or for a cis- or trans-vinylene or --C.tbd.C-- group;B means a chemical bond, a --CHR.sup.5 --, --CHR.sup.5 --CH.sub.2 -- or a --CH.sub.2 --O-- group: andR.sup.5 means hydrogen or a C.sub.1-4 alkyl group.The compounds of the formula (I) can be used therapeutically as platelet aggregation inhibiting, anti-thrombotic, hypotensive and anti-antherosclerotic agents; they are much more stable than the natural prostacyclin derivatives.

    Abstract translation: 本发明涉及通式（I）的新型二亚呋喃基 - 前列环素衍生物，其中R1代表氢或直链或支链C 1-6烷基，无机阳离子或质子化形式的碱 含有氨基; R2代表氢，C1-4烷酰基或苯甲酰基，单取代的苯甲酰基，三烷基甲硅烷基或烷氧基烷基; R3代表直链或支链C 1-6烷基，任意被卤素取代的苯基或被C 1-4烷基任选取代的杂芳基，或被卤素或C1-4烷基或环烷基任选取代的杂芳基; A代表乙烯或顺式 - 或反式 - 亚乙烯基或-C 3位C基团; B表示化学键，-CHR5-，-CHR5-CH2-或-CH2-O-基，R5表示氢或C1-4烷基。 式（I）化合物可以治疗性地用作血小板聚集抑制剂，抗血栓形成剂，降压药和抗动脉粥样硬化剂; 它们比天然前列环素衍生物更稳定。

    Vasodilative 4-thia-PGI.sub.1 and 4-sulfinyl-PGI.sub.1 and derivatives thereof
    6.
    发明授权
    Vasodilative 4-thia-PGI.sub.1 and 4-sulfinyl-PGI.sub.1 and derivatives thereof 失效
    血管扩张型4-thia-PGI1和4-亚磺酰基-PGI1及其衍生物

    公开(公告)号：US4379164A

    公开(公告)日：1983-04-05

    申请号：US314433

    申请日：1981-10-23

    Applicant: Istvan Tomoskozi ,  Peter Gyory ,  Gabor Kovacs ,  Sandor Virag ,  Peter Kormoczy ,  Istvan Stadler

    Inventor： Istvan Tomoskozi ,  Peter Gyory ,  Gabor Kovacs ,  Sandor Virag ,  Peter Kormoczy ,  Istvan Stadler

    IPC: C07D307/935 ,  A61K31/557 ,  A61K31/5575 ,  A61P1/04 ,  A61P9/08 ,  A61P11/08 ,  C07C405/00 ,  C07D307/937 ,  A61K31/335

    CPC classification number: C07D307/937

    Abstract: A compound having vasodilative, bronchodilative, stomach-mucosa-protective and platelet-aggregation-inhibiting activity has the formulaA 4-thia- or 4-sulfinyl-PGI.sub.1 -compound of the formula I ##STR1## wherein Q stands for --S-- or --SO--,A stands for C.sub.1-6 straight or branched chain alkylene,B stands for ethylene, vinylene or ethinylene,R.sup.1 represents hydrogen or C.sub.1-4 alkyl,R.sup.2 represents C.sub.1-8 straight or branched chain alkyl or mono-substituted aryl-oxy-methyl,R.sup.3 stands for hydrogen or acetyl, andZ represents --COOH, --CN, --CH.sub.2 OH or --COOW, wherein W stands for an equivalent of a pharmacologically acceptable cation or C.sub.1-4 alkyl.

    Abstract translation: 具有血管扩张性，支气管扩张性，胃粘膜保护性和血小板聚集抑制活性的化合物具有式I的4-硫杂或4-亚磺酰基-GlyI化合物，其中Q代表 - S-或-SO-，A代表C 1-6直链或支链亚烷基，B代表亚乙基，亚乙烯基或亚乙烯基，R 1代表氢或C 1-4烷基，R 2代表C1-8直链或支链烷基或单 - 取代的芳氧基 - 甲基，R3代表氢或乙酰基，Z代表-COOH，-CN，-CH2OH或-COOW，其中W代表药理学上可接受的阳离子或C 1-4烷基的当量。

    7-Oxo-PGI.sub.2 -derivatives and process for the preparation thereof and pharmaceutical compositions containing same
    8.
    发明授权
    7-Oxo-PGI.sub.2 -derivatives and process for the preparation thereof and pharmaceutical compositions containing same 失效
    7-氧代-PGI2-衍生物及其制备方法和含有它们的药物组合物

    公开(公告)号：US4330553A

    公开(公告)日：1982-05-18

    申请号：US205292

    申请日：1980-11-10

    Applicant: Vilmos Simonidesz ,  Agnes Papp nee Behr ,  Gabor Kovacs ,  Jozsef Ivanics ,  Julia Der nee Foldvary ,  Istvan Stadler ,  Istvan Pallagi

    Inventor： Vilmos Simonidesz ,  Agnes Papp nee Behr ,  Gabor Kovacs ,  Jozsef Ivanics ,  Julia Der nee Foldvary ,  Istvan Stadler ,  Istvan Pallagi

    IPC: C07D307/937 ,  A61K31/34 ,  A61K31/557 ,  C07D307/935

    CPC classification number: C07D307/937

    Abstract: New PGI.sub.2 derivatives and a process for their preparation are disclosed of the formula (I) ##STR1## wherein Q is hydrogen, a pharmacologically acceptable cation, or lower alkyl;A is cis or trans --CH.dbd.CH--, --C.tbd.C--, or --CH.sub.2 --CH.sub.2 --;R.sup.13 is hydrogen or a C.sub.1 to C.sub.4 alkanoyl or is a blockinggroup of the formula R.sup.7 R.sup.8 R.sup.9 Si or ##STR2## wherein R.sup.7, R.sup.8 and R.sup.9 are the same or different and can be straight or branched chain alkyl groups having 1 to 4 carbon atoms and R.sup.10 and R.sup.11 are the same or different and can be hydrogen or methyl, and R.sup.12 represents methyl or ethyl, or is tetrahydropyran-2-yl;R.sup.4 is hydrogen or lower alkyl inthe .alpha. or .beta. steric position;R.sup.1 and R.sup.2 are each hydrogen or lower alkyl;Y is methylene, oxygen or an --NH-- group; andR.sup.3 is lower alkyl or phenyl which can be monosubstituted phenyl. The compounds are useful as antiaggregation or thrombus-dissolving agents, stomach juice secretion inhibiting agents and antiasthmatic agents.

    Abstract translation: 公开了新的PGI 2衍生物及其制备方法，式（I）其中Q为氢，药理学可接受的阳离子或低级烷基; A是顺式或反式-CH = CH - ， - C 3BOND C - 或-CH 2 -CH 2 - ; R 13是氢或C 1至C 4烷酰基或是式R 7 R 8 R 9 Si或其中R 7，R 8和R 9相同或不同并且可以是具有1至4个碳原子的直链或支链烷基和R 10和 R 11相同或不同，可以是氢或甲基，R 12表示甲基或乙基，或是四氢吡喃-2-基; R4是氢或在α或β位置的低级烷基; R1和R2各自为氢或低级烷基; Y是亚甲基，氧或-NH-基团; 并且R 3是可以是单取代的苯基的低级烷基或苯基。 该化合物可用作抗凝聚剂或血栓溶解剂，胃液分泌抑制剂和抗哮喘剂。

    Process for making bicyclic lactone derivatives for use as intermediates in the synthesis of prostaglandins
    10.
    发明授权
    Process for making bicyclic lactone derivatives for use as intermediates in the synthesis of prostaglandins 失效
    用于制备前列腺素合成中的二环内酯衍生物的方法

    公开(公告)号：US4204999A

    公开(公告)日：1980-05-27

    申请号：US952950

    申请日：1978-10-20

    Applicant: Istvan Tomoskozi ,  Gabor Kovacs ,  Istvan Szekely ,  Vilmos Simonidesz ,  Marianna Lovasz nee Gaspar ,  Borbala Keresztesnee Ordog ,  Julia Remport nee Radoczi ,  Istvan Stadler ,  Zsuzsa Visky nee Gombos ,  Csaba Szantay

    Inventor： Istvan Tomoskozi ,  Gabor Kovacs ,  Istvan Szekely ,  Vilmos Simonidesz ,  Marianna Lovasz nee Gaspar ,  Borbala Keresztesnee Ordog ,  Julia Remport nee Radoczi ,  Istvan Stadler ,  Zsuzsa Visky nee Gombos ,  Csaba Szantay

    IPC: C07D307/935 ,  C07D493/04 ,  C07D493/02 ,  C07D307/77

    CPC classification number: C07D307/935 ,  C07D493/04

    Abstract: A process for the preparation of optically active or racemic lactone diol derivatives of the formula ##STR1## (for use as intermediates in the Corey prostaglandin synthesis). Optically active or racemic lactone diol derivatives are inclosed, in whichR.sup.3 and R.sup.4 are the same or different and stand for a hydrogen, or a lower alkanoyl optionally substituted with one, two or three halogen atoms, or form together a ##STR2## group, in which R.sup.5 and R.sup.6 are the same or different and stand for a hydrogen, alkyl or aryl, with a process for preparing them.According to the invention the above compound are prepared by reacting optically active or racemic lactone of the formula II with formaldehyde or with a formaldehyde polymerisate, in the presence of the mixture of a strong acid and water or of a lower alkane carboxylic acid optionally substituted with one, two or three halogen atoms, and then optionally subjecting the obtained compound of the general formula I, in which R.sup.3 and/or R.sup.4 stand for an alkanoyl optionally substituted with one, two or three halogen atoms to partial or total hydrolysis or alcoholysis in an acid or alkaline medium and/or reacting it with the oxo-compounds of the formula R.sup.5 --CHO or R.sup.6 --CO--R.sup.5 or with the acetals of the above compounds.The compounds according to the invention are useful intermediates in the Corey prostaglandine synthesis.

    Abstract translation: 制备式（IMAGE）的光学活性或外消旋内酯二醇衍生物的方法（用作Corey前列腺素合成中的中间体）。 光学活性或外消旋内酯二醇衍生物被封闭，其中R3和R4相同或不同，代表氢，或任选被一个，两个或三个卤素原子取代的低级烷酰基，或一起形成一个< 其中R5和R6相同或不同，代表氢，烷基或芳基，具有制备它们的方法。 根据本发明，上述化合物通过使式II的光学活性或外消旋内酯与甲醛或甲醛聚合物在强酸和水的混合物或任选被 一个，两个或三个卤素原子，然后任选地使得到的通式I的化合物，其中R 3和/或R 4代表任选被一个，两个或三个卤素原子取代的烷酰基部分或全部水解或醇解 酸或碱性介质和/或使其与式R5-CHO或R6-CO-R5的氧代化合物或与上述化合物的缩醛反应。 根据本发明的化合物在Corey前列腺素合成中是有用的中间体。

Patent Agency Ranking